Easton D F, Steele L, Fields P, Ormiston W, Averill D, Daly P A, McManus R, Neuhausen S L, Ford D, Wooster R, Cannon-Albright L A, Stratton M R, Goldgar D E
CRC Genetic Epidemiology Unit, Institute of Public Health, Cambridge, United Kingdom.
Am J Hum Genet. 1997 Jul;61(1):120-8. doi: 10.1086/513891.
The penetrance of the BRCA2 gene on chromosome 13q12-13 has been estimated in two large, systematically ascertained, linked families, by use of a maximum-likelihood method to incorporate both cancer-incidence data and 13q marker typings in the families. The cumulative risk of breast cancer in female gene carriers was estimated to be 59.8% by age 50 years (95% confidence interval [95% CI] 25.9%-78.5%) and 79.5% by age 70 years (95% CI 28.9%-97.5%). The cumulative risk of breast cancer in male carriers was estimated to be 6.3% (95% CI 1.4%-25.6%) by age 70 years. There was no evidence of any risk difference between the two families. These results indicate that the lifetime breast cancer risk in BRCA2 carriers, for at least a subset of mutations, is comparable to that for BRCA1. A significant excess of ovarian cancer in gene carriers was observed (relative risk 17.69, based on three cases), but the absolute risk of ovarian cancer was less than that reported for BRCA1. Significant excesses of laryngeal cancer (relative risk 7.67, based on two possible carriers) and prostate cancer (relative risk 2.89, based on five possible carriers) were also observed. One case of ocular melanoma, as well as a second eye cancer of unspecified histology, occurred in obligate gene carriers.
利用最大似然法,结合两个大型、系统确定的连锁家族中的癌症发病率数据和13q标记分型,对位于13q12 - 13染色体上的BRCA2基因的外显率进行了估计。女性基因携带者患乳腺癌的累积风险在50岁时估计为59.8%(95%置信区间[95%CI]为25.9% - 78.5%),70岁时为79.5%(95%CI为28.9% - 97.5%)。男性携带者患乳腺癌的累积风险在70岁时估计为6.3%(95%CI为1.4% - 25.6%)。没有证据表明两个家族之间存在任何风险差异。这些结果表明,至少对于一部分突变而言,BRCA2基因携带者患乳腺癌的终生风险与BRCA1基因携带者相当。观察到基因携带者患卵巢癌的风险显著增加(基于3例病例,相对风险为17.69),但卵巢癌的绝对风险低于报道的BRCA1基因携带者。还观察到喉癌(基于2例可能的携带者,相对风险为7.67)和前列腺癌(基于5例可能的携带者,相对风险为2.89)的风险显著增加。在确定的基因携带者中出现了1例眼黑色素瘤以及1例组织学未明确的眼部癌症。